POINT LAUNCHES STUDY

Article

Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.